Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors

This is a multicenter, open-label, Phase 1/2 master protocol evaluating autologous dual-target CAR-T cell therapy in adults with advanced solid cancers. After central biomarker screening, each participant is assigned the best-matched dual-target construct from a predefined target-pair library. The trial is designed to test whether biomarkerguided dual targeting can improve tumor control, reduce antigenescape risk, and preserve safety in solid tumors.

NCT Number	NCT07523529
Lead Sponsor	Beijing Biotech
Conditions	Advanced Unresectable, Metastatic
Enrollment	72 participants
Start Date	2026-03-02
Primary Completion	2027-04-14 (estimated)
Study Completion	2028-03-17 (estimated)
Updated on ClinicalTrials.gov	2026-04-13